Bioray Biotech Co., Ltd (TPEX: 7561)
Taiwan
· Delayed Price · Currency is TWD 21.30
0.00 (0.00%)
Dec 31, 2024, 2:21 PM CST
Bioray Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 183.57 | 191.83 | 190.6 | 148.02 | 156.3 | 181.93 | Upgrade
|
| Revenue Growth (YoY) | -6.24% | 0.65% | 28.77% | -5.30% | -14.09% | -1.92% | Upgrade
|
| Cost of Revenue | 115.97 | 114.18 | 110.09 | 80.73 | 88.44 | 100.66 | Upgrade
|
| Gross Profit | 67.59 | 77.65 | 80.51 | 67.29 | 67.86 | 81.28 | Upgrade
|
| Selling, General & Admin | 50.73 | 52.73 | 48.48 | 53.55 | 53.36 | 62.43 | Upgrade
|
| Research & Development | 42.26 | 44.27 | 32.26 | 21.86 | 14.41 | 12.09 | Upgrade
|
| Operating Expenses | 93.11 | 96.98 | 80.82 | 75.4 | 68.08 | 74.43 | Upgrade
|
| Operating Income | -25.52 | -19.33 | -0.31 | -8.11 | -0.22 | 6.85 | Upgrade
|
| Interest Expense | -1.36 | -1.32 | -1.36 | -0.95 | -1.17 | -1.12 | Upgrade
|
| Interest & Investment Income | 0.85 | 0.65 | 0.19 | 0.05 | 0.14 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0.18 | -0.13 | -0.18 | -0.53 | 0.82 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.31 | 7.09 | 2.12 | 3.02 | 3.19 | 5.38 | Upgrade
|
| EBT Excluding Unusual Items | -18.74 | -13.09 | 0.5 | -6.17 | 1.4 | 12.1 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.3 | -1.3 | - | - | 0.21 | 9.95 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0 | 0.2 | 0.18 | - | -3.06 | -0.35 | Upgrade
|
| Pretax Income | -19.43 | -14.19 | 0.68 | -6.17 | -1.46 | 21.71 | Upgrade
|
| Income Tax Expense | -3.63 | -2.63 | 0.18 | 1.76 | -0.04 | 7.98 | Upgrade
|
| Earnings From Continuing Operations | -15.8 | -11.56 | 0.5 | -7.93 | -1.41 | 13.72 | Upgrade
|
| Minority Interest in Earnings | - | - | - | 0.74 | 1.36 | 5.77 | Upgrade
|
| Net Income | -15.8 | -11.56 | 0.5 | -7.19 | -0.06 | 19.49 | Upgrade
|
| Net Income to Common | -15.8 | -11.56 | 0.5 | -7.19 | -0.06 | 19.49 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -10.38% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 28 | 27 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 28 | 27 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 1.54% | 7.37% | 4.67% | 0.14% | -0.09% | 23.09% | Upgrade
|
| EPS (Basic) | -0.53 | -0.38 | 0.02 | -0.27 | -0.00 | 0.73 | Upgrade
|
| EPS (Diluted) | -0.53 | -0.38 | 0.02 | -0.27 | -0.00 | 0.73 | Upgrade
|
| EPS Growth | - | - | - | - | - | -27.10% | Upgrade
|
| Free Cash Flow | 3.84 | -10.78 | -57.16 | -6.15 | -49.32 | -0.45 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | -0.36 | -2.04 | -0.23 | -1.85 | -0.02 | Upgrade
|
| Dividend Per Share | - | - | 0.200 | - | - | 0.300 | Upgrade
|
| Dividend Growth | - | - | - | - | - | -17.76% | Upgrade
|
| Gross Margin | 36.82% | 40.48% | 42.24% | 45.46% | 43.42% | 44.67% | Upgrade
|
| Operating Margin | -13.90% | -10.08% | -0.16% | -5.48% | -0.14% | 3.76% | Upgrade
|
| Profit Margin | -8.61% | -6.03% | 0.26% | -4.86% | -0.04% | 10.71% | Upgrade
|
| Free Cash Flow Margin | 2.09% | -5.62% | -29.99% | -4.15% | -31.56% | -0.25% | Upgrade
|
| EBITDA | -7.39 | -1.66 | 15.79 | 5.32 | 9.36 | 15.25 | Upgrade
|
| EBITDA Margin | -4.03% | -0.86% | 8.29% | 3.59% | 5.99% | 8.38% | Upgrade
|
| D&A For EBITDA | 18.12 | 17.67 | 16.11 | 13.43 | 9.58 | 8.4 | Upgrade
|
| EBIT | -25.52 | -19.33 | -0.31 | -8.11 | -0.22 | 6.85 | Upgrade
|
| EBIT Margin | -13.90% | -10.08% | -0.16% | -5.48% | -0.14% | 3.76% | Upgrade
|
| Effective Tax Rate | - | - | 26.69% | - | - | 36.78% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.